--- title: "Annovis Bio (ANVS) news: going concern and offering" url: "https://aibio.space/companies/annovis-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ANVS going concern and offering news: Annovis Bio gets NYSE continued listing notice, will submit compliance plan within 45 days. Annovis Bio, Inc." --- ANVS Annovis Bio, Inc. NYSE · United States # Annovis Bio (ANVS) news ANVS going concern and offering news Listings · 2025-06-20 ## [NYSE accepts Annovis Bio plan to regain listing compliance](https://aibio.space/news/nyse-accepts-annovis-bio-plan-regain-listing-compliance/) The NYSE accepted Annovis Bio's plan to regain compliance with its market capitalization and stockholders' equity standards, giving the company 18 months from a March 26, 2025 notice, quarterly progress reports and a warning that trading could still be suspended. ## Latest Annovis Bio news 1. 2025-03-27 Listings [Annovis Bio gets NYSE continued listing notice, will submit compliance plan within 45 days](https://aibio.space/news/annovis-bio-gets-nyse-continued-listing-notice-will-submit-compliance/) The NYSE says Annovis's 30-day average market capitalization was approximately $37.9 million and its stockholders' equity was $9.3 million, both under the $50 million floor. The company's 10-K already carries a going-concern warning and says its cash lasts into the fourth quarter of 2025. 2. 2025-02-03 Financings [Annovis Bio prices $21,000,000 public offering of units at $4.00](https://aibio.space/news/annovis-bio-prices-21-000-000-public-offering-units-4-00/) Annovis Bio priced 5,250,000 units at $4.00 for $21,000,000 on February 3, 2025, through ThinkEquity as underwriter, with a $1,260,000 discount and warrants exercisable at $5.00, which is 125% of the offering price. ## Annovis Bio at a glance - **Ticker**: ANVS - **Listing**: NYSE - **Country**: United States - **Cash, Jun 30, 2026**: $18.7 million ### Related companies - [Bolt Biotherapeutics](https://aibio.space/companies/bolt-biotherapeutics/) NASDAQ: BOLT - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) NASDAQ: REGN - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) AMEX: ATNM - [Context Therapeutics](https://aibio.space/companies/context-therapeutics/) NASDAQ: CNTX - [Panbela Therapeutics](https://aibio.space/companies/panbela-therapeutics/) OTC: PBLA - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB - [Grace Therapeutics](https://aibio.space/companies/grace-therapeutics/) NASDAQ: GRCE ### Also on NYSE - [AbbVie](https://aibio.space/companies/abbvie/) ABBV - [Enovis CORP](https://aibio.space/companies/enovis/) ENOV - [Rafael Holdings](https://aibio.space/companies/rafael/) RFL - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NUVB - [Stereotaxis](https://aibio.space/companies/stereotaxis/) STXS - [KONINKLIJKE PHILIPS NV](https://aibio.space/companies/koninklijke-philips/) PHG ## Annovis Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | [$0](https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/) | | Research and development | [$25.2 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | [$20.0 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | | Net income (loss) | [-$28.9 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | [-$24.6 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | | Cash from operations | [-$25.6 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | [-$21.9 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | | Cash and equivalents | [$19.5 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926097228/) | [$10.6 million](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Annovis Bio Has Annovis Bio issued a going-concern warning? Our latest story on this, dated Mar 27, 2025: "Annovis Bio gets NYSE continued listing notice, will submit compliance plan within 45 days". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/annovis-bio-gets-nyse-continued-listing-notice-will-submit-compliance/). Has Annovis Bio raised money recently? Our latest story on this, dated Feb 3, 2025: "Annovis Bio prices $21,000,000 public offering of units at $4.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/annovis-bio-prices-21-000-000-public-offering-units-4-00/). What is the ticker symbol of Annovis Bio? Annovis Bio, Inc. trades under the ticker ANVS on NYSE. Where is Annovis Bio listed? Annovis Bio, Inc. is listed on NYSE. Our directory also records these other listings: GETTEX:07X. What is the SEC CIK of Annovis Bio? The SEC Central Index Key (CIK) for Annovis Bio, Inc. is 1477845. Its filings are on SEC EDGAR. How many shares does Annovis Bio have outstanding? 42,606,152 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Annovis Bio listed under? Our directory records Annovis Bio, Inc. under United States. What does Annovis Bio do? Our directory classifies Annovis Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Annovis Bio? The ISIN recorded for Annovis Bio, Inc. is US03615A1088. Does aibio.space cover Annovis Bio? aibio.space lists Annovis Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Annovis Bio incorporated? SEC records list its state or country of incorporation as DE. What was Annovis Bio's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Annovis Bio profitable? Annovis Bio, Inc. reported a net loss of $28.9 million for the fiscal year ended Dec 31, 2025, and used $25.6 million of cash in operations, per its annual report to the SEC. How much does Annovis Bio spend on research and development? $25.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Annovis Bio have? $18.7 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Annovis Bio Members talk about Annovis Bio (ANVS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Annovis Bio, newest first. Each line links the filing it comes from. 1. 2026-10-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465926120732/tm2628596d1_ex99-1.htm) 2. 2026-04-09 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465926041561/tm2611267-1_424b5.htm) 3. 2026-03-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/anvs-20251231x10k.htm) 4. 2026-03-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465926027751/anvs-20251231x10k.htm) 5. 2025-10-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465925099237/tm2528502-1_424b5.htm) 6. 2025-06-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/tm2518347d1_ex99-1.htm) 7. 2025-03-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465925028803/tm2510633d1_ex99-1.htm) 8. 2025-03-21 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm) 9. 2025-03-21 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231x10k.htm) 10. 2025-02-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465925008278/tm254033-1_424b5.htm) 11. 2024-12-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1477845/000110465924127434/tm2430444-1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:ANVS on TradingView](https://www.tradingview.com/symbols/NYSE-ANVS/). ## SEC filings and registration - **SEC name**: Annovis Bio, Inc. - **CIK**: 1477845 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ANVS (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355 - **Phone**: 484-875-3192 - **Shares outstanding**: 42,606,152 as of 2026-08-14 (10-Q filed 2026-08-14) - **Former names**: QR Pharma, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926116995/tm2627875d1_8k.htm) filed 2026-10-20 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1477845/000110465926107113/tm2623911-2_def14a.htm) filed 2026-09-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1477845/000110465926097228/anvs-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_8k.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/tm2620172d1_8k.htm) filed 2026-07-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926075198/tm2617993d2_8k.htm) filed 2026-06-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/tm2615162d1_8k.htm) filed 2026-05-20 - [424B5](https://www.sec.gov/Archives/edgar/data/1477845/000110465926064510/tm2614901-2_424b5.htm) filed 2026-05-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001477845), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Annovis Bio, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker ANVS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Annovis Bio, Inc. - **Ticker**: ANVS - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03615A1088 - **Other listed symbols**: GETTEX:07X - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-ANVS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/annovis-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Annovis Bio (ANVS) news: going concern and offering", 2026-10-31, https://aibio.space/companies/annovis-bio/